Aratana Therapeutics

Based: Kansas City, KS
Stock symbol: PETX
Range: $11 to $13
IPO price: $6.00
Close Oct. 17: $28.07
Change: Up 367%
Raised: $39.6 million

The scoop: Aratana looked like a loser when its IPO struggled to gain acceptance on Wall Street. Forced to slash its stock price to win over investors, the company has since seen its shares soar. In the short time since the IPO was completed in June, the company--which develops new therapies for pets--acquired a rival outfit for $30 million and is in a position to reap some major benefits with follow-on stock offerings. The biotech has benefited enormously from a second look from investors. And the Vet Therapeutics buyout put it in close range of commercialization efforts. Sometimes, even a weak IPO can open the door to fresh fundraising opportunities. The industry has not overlooked the lesson provided by Aratana.

For more:
Aratana adds pet therapies in $38M deal to acquire Vet
Aratana joins biotech IPO queue while Tetraphase takes a haircut
Aratana adds $15M in VC cash for new pet drug deals with biopharmas

Aratana Therapeutics

Suggested Articles

Shares in ReNeuron fell more than one-third after the release of top-line data at the start of the month but the biotech argued the data are positive.

As Covance changes up its leadership amid a change at the top of its parent company, one of its former execs has jumped ship to midsize rival CRO.

Researchers are studying the retrovirus KoRV-A, which is spreading among koalas, to gain new insights into how DNA evolves.